Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1996 1
1997 1
1998 3
1999 2
2001 4
2002 13
2003 17
2004 10
2005 17
2006 12
2007 21
2008 16
2009 28
2010 22
2011 30
2012 37
2013 40
2014 34
2015 40
2016 27
2017 29
2018 30
2019 29
2020 29
2021 29
2022 29
2023 22
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

522 results

Results by year

Filters applied: . Clear all
Page 1
Increasing power in screening trials by testing control-arm specimens: Application to multicancer detection screening.
Katki HA, Prorok PC, Castle PE, Minasian LM, Pinsky PF. Katki HA, et al. Among authors: castle pe. J Natl Cancer Inst. 2024 Apr 11:djae083. doi: 10.1093/jnci/djae083. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 38603624
BACKGROUND: Cancer screening trials have required large sample-sizes and long time-horizons to demonstrate cancer mortality reductions, the primary goal of cancer screening. ...Under two assumptions that we detail herein, we projected the IE analysis for 3 ex …
BACKGROUND: Cancer screening trials have required large sample-sizes and long time-horizons to demonstrate cancer mortality re …
A Proposed Framework and Lexicon for Cancer Prevention.
Castle PE, Faupel-Badger JM, Umar A, Rebbeck TR. Castle PE, et al. Cancer Discov. 2024 Apr 4;14(4):594-599. doi: 10.1158/2159-8290.CD-23-1492. Cancer Discov. 2024. PMID: 38571411
Cancer prevention is central to efforts to control the burden of cancer. ...
Cancer prevention is central to efforts to control the burden of cancer. ...
NCI Resources for Cancer Immunoprevention Research.
Sei S, Srivastava S, Kelly HR, Miller MS, Leitner WW, Shoemaker RH, Szabo E, Castle PE. Sei S, et al. Among authors: castle pe. Cancer Immunol Res. 2024 Apr 2;12(4):387-392. doi: 10.1158/2326-6066.CIR-23-0708. Cancer Immunol Res. 2024. PMID: 38562082
Cancer prevention and early detection, the first two of the eight primary goals of the National Cancer Plan released in April 2023, are at the forefront of the nation's strategic efforts to reduce cancer incidence and mortality. ...Recent advances in tumor im …
Cancer prevention and early detection, the first two of the eight primary goals of the National Cancer Plan released in April …
Advances and challenges in cancer immunoprevention and immune interception.
Stanton SE, Castle PE, Finn OJ, Sei S, Emens LA. Stanton SE, et al. Among authors: castle pe. J Immunother Cancer. 2024 Mar 21;12(3):e007815. doi: 10.1136/jitc-2023-007815. J Immunother Cancer. 2024. PMID: 38519057 Free PMC article. Review.
This may change due to recent promising advances in cancer immunoprevention including the use of vaccines for the prevention of viral cancers, the use of cancer-associated antigen vaccines in the setting of precancers, and the development of cancer-pre …
This may change due to recent promising advances in cancer immunoprevention including the use of vaccines for the prevention of viral …
Cancer screening with multicancer detection tests: A translational science review.
Rubinstein WS, Patriotis C, Dickherber A, Han PKJ, Katki HA, LeeVan E, Pinsky PF, Prorok PC, Skarlupka AL, Temkin SM, Castle PE, Minasian LM. Rubinstein WS, et al. Among authors: castle pe. CA Cancer J Clin. 2024 Mar 22. doi: 10.3322/caac.21833. Online ahead of print. CA Cancer J Clin. 2024. PMID: 38517462 Free article. Review.
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective …
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer conc …
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Ghobrial IM, et al. Among authors: castle pe. Blood Cancer Discov. 2024 Mar 4:OF1-OF7. doi: 10.1158/2643-3230.BCD-24-0022. Online ahead of print. Blood Cancer Discov. 2024. PMID: 38441243
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
Befano B, Wentzensen N, Lorey T, Poitras N, Cheung LC, Schiffman M, Clarke MA, Cohen C, Kinney W, Locke A, Castle PE. Befano B, et al. Among authors: castle pe. Gynecol Oncol. 2024 Jan 31;184:89-95. doi: 10.1016/j.ygyno.2024.01.038. Online ahead of print. Gynecol Oncol. 2024. PMID: 38301311
OBJECTIVES: The longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on precancer and cancer rates by histologic type has not been well described. Calendar trends in diagnoses were examined using data fro …
OBJECTIVES: The longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on …
Association of metformin use and cancer incidence: a systematic review and meta-analysis.
O'Connor L, Bailey-Whyte M, Bhattacharya M, Butera G, Hardell KNL, Seidenberg AB, Castle PE, Loomans-Kropp HA. O'Connor L, et al. Among authors: castle pe. J Natl Cancer Inst. 2024 Apr 5;116(4):518-529. doi: 10.1093/jnci/djae021. J Natl Cancer Inst. 2024. PMID: 38291943
In addition to its role in diabetes management, metformin may reduce cancer risk. METHODS: We conducted a comprehensive systematic review and meta-analysis to investigate the association between metformin use and cancer risk, with evaluation by specific cancer …
In addition to its role in diabetes management, metformin may reduce cancer risk. METHODS: We conducted a comprehensive systematic re …
2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023.
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki AB, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. Perkins RB, et al. Among authors: castle pe. J Low Genit Tract Dis. 2024 Jan 1;28(1):3-6. doi: 10.1097/LGT.0000000000000788. J Low Genit Tract Dis. 2024. PMID: 38117563
Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening.
Knudsen AB, Trentham-Dietz A, Kim JJ, Mandelblatt JS, Meza R, Zauber AG, Castle PE, Feuer EJ. Knudsen AB, et al. Among authors: castle pe. JAMA Netw Open. 2023 Nov 1;6(11):e2344698. doi: 10.1001/jamanetworkopen.2023.44698. JAMA Netw Open. 2023. PMID: 37991759 Free PMC article.
IMPORTANCE: Increased use of recommended screening could help achieve the Cancer Moonshot goal of reducing US cancer deaths. OBJECTIVE: To estimate the number of cancer deaths that could be prevented with a 10-percentage point increase in the use of US Preven …
IMPORTANCE: Increased use of recommended screening could help achieve the Cancer Moonshot goal of reducing US cancer deaths. O …
A novel tailed primer nucleic acid test for detection of HPV 16, 18 and 45 DNA at the point of care.
Chang MM, Ma A, Novak EN, Barra M, Kundrod KA, Montealegre JR, Scheurer ME, Castle PE, Schmeler K, Richards-Kortum R. Chang MM, et al. Among authors: castle pe. Sci Rep. 2023 Nov 21;13(1):20397. doi: 10.1038/s41598-023-47582-y. Sci Rep. 2023. PMID: 37989845 Free PMC article.
Cervical cancer is a leading cause of death for women in low-resource settings despite being preventable through human papillomavirus (HPV) vaccination, early detection, and treatment of precancerous lesions. The World Health Organization recommends high-risk HPV …
Cervical cancer is a leading cause of death for women in low-resource settings despite being preventable through human papillomavirus …
The Mulher Study: cervical cancer screening with primary HPV testing in Mozambique.
Salcedo MP, Lathrop E, Osman N, Neves A, Rangeiro R, Mariano AAN, Nkundabatware JC, Tivir G, Carrilho C, Monteiro ECS, Burny R, Thomas JP, Carns J, Andrade V, Mavume C, Paulo Mugolo R, Atif H, Hoover H, Chivambo E, Chissano M, Oliveira C, Milan J, Varon ML, Fellman BM, Baker E, Jeronimo J, Castle PE, Richards-Kortum R, Schmeler KM, Lorenzoni C. Salcedo MP, et al. Among authors: castle pe. Int J Gynecol Cancer. 2023 Dec 4;33(12):1869-1874. doi: 10.1136/ijgc-2023-004958. Int J Gynecol Cancer. 2023. PMID: 37907263
OBJECTIVE: To evaluate cervical cancer screening with primary human papillomavirus (HPV) testing in Mozambique, a country with one of the highest burdens of cervical cancer globally. ...Thirty-one patients (1.2%) were diagnosed with cancer and referred …
OBJECTIVE: To evaluate cervical cancer screening with primary human papillomavirus (HPV) testing in Mozambique, a country with …
Expanding Cervical Cancer Screening in Mozambique: Challenges Associated With Diagnosing and Treating Cervical Cancer.
Batman S, Rangeiro R, Monteiro E, Changule D, Daud S, Ribeiro M, Tsambe E, Bila C, Osman N, Carrilho C, Neves A, Atif H, De Jesus C, Mariano A, Moretti-Marques R, Vieira M, Fontes-Cintra G, Lopes A, Batware JC, Luis E, Grover S, Baker E, Fellman B, Montealegre J, Castle PE, Jeronimo J, Chiao E, Lorenzoni C, Schmeler K, Salcedo MP. Batman S, et al. Among authors: castle pe. JCO Glob Oncol. 2023 Sep;9:e2300139. doi: 10.1200/GO.23.00139. JCO Glob Oncol. 2023. PMID: 37824802 Free PMC article.
The objective of this study was to describe the outcomes of women diagnosed with invasive cancer as part of the Mozambican women undergoing cervical cancer screening with human papillomavirus (HPV) testing in conjunction with family planning services (MULHER) …
The objective of this study was to describe the outcomes of women diagnosed with invasive cancer as part of the Mozambican women unde …
Trends in treatment-seeking for fever in children under five years old in 151 countries from 1990 to 2020.
Nguyen M, Dzianach PA, Castle PECW, Rumisha SF, Rozier JA, Harris JR, Gibson HS, Twohig KA, Vargas-Ruiz CA, Bisanzio D, Cameron E, Weiss DJ, Bhatt S, Gething PW, Battle KE. Nguyen M, et al. Among authors: castle pecw. PLOS Glob Public Health. 2023 Aug 23;3(8):e0002134. doi: 10.1371/journal.pgph.0002134. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37611001 Free PMC article.
Toward 70% cervical cancer screening coverage: Technical challenges and opportunities to increase access to human papillomavirus (HPV) testing.
Kundrod KA, Jeronimo J, Vetter B, Maza M, Murenzi G, Phoolcharoen N, Castle PE. Kundrod KA, et al. Among authors: castle pe. PLOS Glob Public Health. 2023 Aug 16;3(8):e0001982. doi: 10.1371/journal.pgph.0001982. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37585432 Free PMC article. Review.
The World Health Organization (WHO) has called for the elimination of cervical cancer as a public health problem. Cervical cancer screening through human papillomavirus (HPV) testing is a core component of the strategy for elimination, with a set target of sc …
The World Health Organization (WHO) has called for the elimination of cervical cancer as a public health problem. Cervical cancer …
A novel human papillomavirus and host DNA methylation score and detection of cervical adenocarcinoma.
Gradissimo A, Clarke MA, Xue X, Castle PE, Raine-Bennett TR, Schiffman M, Wentzensen N, Strickler HD, Burk RD. Gradissimo A, et al. Among authors: castle pe. J Natl Cancer Inst. 2023 Dec 6;115(12):1535-1543. doi: 10.1093/jnci/djad134. J Natl Cancer Inst. 2023. PMID: 37467068
This study assessed a novel human papillomavirus (HPV) and host DNA Methylation Score for AIS and ADC screening. METHODS: We measured methylation levels at CpG sites in the L2/L1 open reading frames of HPV16, HPV18, and HPV45-as well as 2 human loci, DCC and HS3ST2. Specif …
This study assessed a novel human papillomavirus (HPV) and host DNA Methylation Score for AIS and ADC screening. METHODS: We measured …
An integrated isothermal nucleic acid amplification test to detect HPV16 and HPV18 DNA in resource-limited settings.
Kundrod KA, Barra M, Wilkinson A, Smith CA, Natoli ME, Chang MM, Coole JB, Santhanaraj A, Lorenzoni C, Mavume C, Atif H, Montealegre JR, Scheurer ME, Castle PE, Schmeler KM, Richards-Kortum RR. Kundrod KA, et al. Among authors: castle pe. Sci Transl Med. 2023 Jun 21;15(701):eabn4768. doi: 10.1126/scitranslmed.abn4768. Epub 2023 Jun 21. Sci Transl Med. 2023. PMID: 37343083 Free PMC article.
High-risk human papillomavirus (HPV) DNA testing is widely acknowledged as the most sensitive cervical cancer screening method but has limited availability in resource-limited settings, where the burden of cervical cancer is highest. ...These results show the …
High-risk human papillomavirus (HPV) DNA testing is widely acknowledged as the most sensitive cervical cancer screening method …
The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
Schiffman M, Mirabello L, Egemen D, Befano B, Xiao Y, Wentzensen N, Raine-Bennett T, Nayar R, Cheung LC, Rositch A, Beaty T, Perkins RB, de Sanjose S, Lorey T, Castle PE, Burk RD. Schiffman M, et al. Among authors: castle pe. Gynecol Oncol. 2023 Jul;174:253-261. doi: 10.1016/j.ygyno.2023.05.011. Epub 2023 May 25. Gynecol Oncol. 2023. PMID: 37243996
HPV typing of a sample of residual HPV test specimens was performed on a separate cohort selected from KPNC (Persistence and Progression, PaP, cohort). ...RESULTS: Among HPV-positive individuals in PaP cohort, 99% of prevalent AC and 96% of AIS were linked to …
HPV typing of a sample of residual HPV test specimens was performed on a separate cohort selected from KPNC (Persistence and P …
Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.
Cuzick J, Adcock R, Kinney W, Castle PE, Robertson M, McDonald RM, Stoler MH, Du R, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Cuzick J, et al. Among authors: castle pe. Int J Cancer. 2023 Jul 1;153(1):83-93. doi: 10.1002/ijc.34519. Epub 2023 Apr 7. Int J Cancer. 2023. PMID: 36946690
Human papillomavirus (HPV) testing for cervical screening increases diagnosis of precancer and reduces the incidence of cervical cancer more than cytology alone. ...CIN3+ was rarely diagnosed in HPV-negative women with abnormal cytology, supporting U.S. prima …
Human papillomavirus (HPV) testing for cervical screening increases diagnosis of precancer and reduces the incidence of cervical c …
Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals.
Landy R, Wang VL, Baldwin DR, Pinsky PF, Cheung LC, Castle PE, Skarzynski M, Robbins HA, Katki HA. Landy R, et al. Among authors: castle pe. JAMA Netw Open. 2023 Mar 1;6(3):e233273. doi: 10.1001/jamanetworkopen.2023.3273. JAMA Netw Open. 2023. PMID: 36929398 Free PMC article.
MAIN OUTCOMES AND MEASURES: Primary outcomes included model prediction performance, the absolute risk of a 1-year delay in cancer diagnosis, and the proportion of people without lung cancer assigned a biennial screening interval vs the proportion of cancer di …
MAIN OUTCOMES AND MEASURES: Primary outcomes included model prediction performance, the absolute risk of a 1-year delay in cancer dia …
Shopping for New Cancer Screening Tests.
Etzioni R, Castle PE. Etzioni R, et al. Among authors: castle pe. J Clin Oncol. 2023 May 10;41(14):2471-2473. doi: 10.1200/JCO.23.00240. Epub 2023 Mar 2. J Clin Oncol. 2023. PMID: 36862969 No abstract available.
HPV-based Cervical Cancer Screening on Self-samples in the Netherlands: Challenges to Reach Women and Test Performance Questions.
Arbyn M, Costa S, Latsuzbaia A, Kellen E, Girogi Rossi P, Cocuzza CE, Basu P, Castle PE. Arbyn M, et al. Among authors: castle pe. Cancer Epidemiol Biomarkers Prev. 2023 Feb 6;32(2):159-163. doi: 10.1158/1055-9965.EPI-22-1041. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 36744312
In 2017, cervical cancer screening in the Netherlands switched from cytology to human papillomavirus (HPV) testing using the validated PCR-based cobas 4800. ...The Dutch findings demonstrate the importance of optimizing outreach, specimen handling and testing protoc …
In 2017, cervical cancer screening in the Netherlands switched from cytology to human papillomavirus (HPV) testing using the v …
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening.
Velentzis LS, Hawkes D, Caruana M, Brotherton JM, Smith MA, Roeske L, Karim KA, Garland SM, Wrede CD, Tan J, Wheeler C, Castle PE, Saville M, Canfell K. Velentzis LS, et al. Among authors: castle pe. Tumour Virus Res. 2023 Jun;15:200255. doi: 10.1016/j.tvr.2023.200255. Epub 2023 Feb 1. Tumour Virus Res. 2023. PMID: 36736490 Free PMC article.
Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec'2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and com …
Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec'2017. We investi …
A low-cost, paper-based hybrid capture assay to detect high-risk HPV DNA for cervical cancer screening in low-resource settings.
Smith CA, Chang MM, Kundrod KA, Novak EN, Parra SG, López L, Mavume C, Lorenzoni C, Maza M, Salcedo MP, Carns JL, Baker E, Montealegre J, Scheurer M, Castle PE, Schmeler KM, Richards-Kortum RR. Smith CA, et al. Among authors: castle pe. Lab Chip. 2023 Jan 31;23(3):451-465. doi: 10.1039/d2lc00885h. Lab Chip. 2023. PMID: 36562325 Free PMC article.
Cervical cancer is a leading cause of cancer death for women in low-resource settings. ...We evaluated performance of the paper HPV DNA assay with short synthetic and genomic HPV DNA targets, HPV positive and negative cellular samples, and two s …
Cervical cancer is a leading cause of cancer death for women in low-resource settings. ...We evaluated performance of the pape …
Safety and Acceptability of Three Ablation Treatments for High-Grade Cervical Precancer: Early Data From a Randomized Noninferiority Clinical Trial.
Soler M, Alfaro K, Masch RJ, Conzuelo Rodriguez G, Qu X, Wu S, Sun J, Hernández Jovel DM, Bonilla J, Puentes LO, Murillo R, Alonzo TA, Felix JC, Castle P, Cremer M. Soler M, et al. Among authors: castle p. JCO Glob Oncol. 2022 Dec;8:e2200112. doi: 10.1200/GO.22.00112. JCO Glob Oncol. 2022. PMID: 36525620 Free PMC article. Clinical Trial.
Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening.
Costa S, Verberckmoes B, Castle PE, Arbyn M. Costa S, et al. Among authors: castle pe. Br J Cancer. 2023 Mar;128(5):805-813. doi: 10.1038/s41416-022-02094-w. Epub 2022 Dec 14. Br J Cancer. 2023. PMID: 36517552 Free PMC article.
BACKGROUND: Human papillomavirus (HPV) testing on self-samples represents a great opportunity to increase cervical cancer screening uptake among under-screened women. METHODS: A systematic review and meta-analysis on randomised controlled trials (RCTs) were performe …
BACKGROUND: Human papillomavirus (HPV) testing on self-samples represents a great opportunity to increase cervical cancer scre …
Impact of the Mobile Game FightHPV on Cervical Cancer Screening Attendance: Retrospective Cohort Study.
Orumaa M, Campbell S, Støer NC, Castle PE, Sen S, Tropé A, Adedimeji A, Nygård M. Orumaa M, et al. Among authors: castle pe. JMIR Serious Games. 2022 Dec 13;10(4):e36197. doi: 10.2196/36197. JMIR Serious Games. 2022. PMID: 36512401 Free PMC article.
CONCLUSIONS: Exposure to the FightHPV app significantly increased cervical cancer screening attendance across the various analyses and improved detection of women with high risk for cervical cancer. ...Gamification can significantly improve the understanding of comp …
CONCLUSIONS: Exposure to the FightHPV app significantly increased cervical cancer screening attendance across the various analyses an …
Sex Biases in Cancer and Autoimmune Disease Incidence Are Strongly Positively Correlated with Mitochondrial Gene Expression across Human Tissues.
Crawford DR, Sinha S, Nair NU, Ryan BM, Barnholtz-Sloan JS, Mount SM, Erez A, Aldape K, Castle PE, Rajagopal PS, Day CP, Schäffer AA, Ruppin E. Crawford DR, et al. Among authors: castle pe. Cancers (Basel). 2022 Nov 29;14(23):5885. doi: 10.3390/cancers14235885. Cancers (Basel). 2022. PMID: 36497367 Free PMC article.
Cancer occurs more frequently in men while autoimmune diseases (AIDs) occur more frequently in women. To explore whether these sex biases have a common basis, we collected 167 AID incidence studies from many countries for tissues that have both a cancer type and an …
Cancer occurs more frequently in men while autoimmune diseases (AIDs) occur more frequently in women. To explore whether these sex bi …
Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.
Minasian LM, Pinsky P, Katki HA, Dickherber T, Han PKJ, Harris L, Patriotis C, Srivastava S, Weil CJ, Prorok PC, Castle PE. Minasian LM, et al. Among authors: castle pe. J Natl Cancer Inst. 2023 Mar 9;115(3):250-257. doi: 10.1093/jnci/djac218. J Natl Cancer Inst. 2023. PMID: 36458902 Free PMC article.
Blood-based assays using various technologies and biomarkers are in commercial development for the purpose of detecting multiple cancer types concurrently at an early stage of disease. These multicancer early detection (MCED) assays have the potential to improve the detect …
Blood-based assays using various technologies and biomarkers are in commercial development for the purpose of detecting multiple cancer …
Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.
Cohen CM, Wentzensen N, Castle PE, Schiffman M, Zuna R, Arend RC, Clarke MA. Cohen CM, et al. Among authors: castle pe. J Clin Oncol. 2023 Feb 10;41(5):1059-1068. doi: 10.1200/JCO.22.01424. Epub 2022 Dec 1. J Clin Oncol. 2023. PMID: 36455190 Free PMC article.
PURPOSE: We conducted an integrated population-based analysis of histologic subtype-specific cervical cancer incidence, survival, and incidence-based mortality by race and ethnicity, with correction for hysterectomy prevalence. METHODS: Using the SEER 21 and 18 registries, …
PURPOSE: We conducted an integrated population-based analysis of histologic subtype-specific cervical cancer incidence, survival, and …
Agreement between Xpert and AmpFire tests for high-risk human papillomavirus among HIV-positive women in Rwanda.
Murangwa A, Desai KT, Gage JC, Murenzi G, Tuyisenge P, Kanyabwisha F, Musafili A, Kubwimana G, Mutesa L, Anastos K, Kim HY, Castle PE. Murangwa A, et al. Among authors: castle pe. Afr J Lab Med. 2022 Oct 19;11(1):1827. doi: 10.4102/ajlm.v11i1.1827. eCollection 2022. Afr J Lab Med. 2022. PMID: 36353194 Free PMC article.
This sub-study included 298 participants who underwent initial screening for cervical cancer using the Xpert HPV assay and visual inspection with acetic acid in 2017 and tested positive by either or both. Participants were rescreened using colposcopy, and cervical s …
This sub-study included 298 participants who underwent initial screening for cervical cancer using the Xpert HPV assay and vis …
Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data.
Hughes SM, Levy CN, Katz R, Lokken EM, Anahtar MN, Hall MB, Bradley F, Castle PE, Cortez V, Doncel GF, Fichorova R, Fidel PL Jr, Fowke KR, Francis SC, Ghosh M, Hwang LY, Jais M, Jespers V, Joag V, Kaul R, Kyongo J, Lahey T, Li H, Makinde J, McKinnon LR, Moscicki AB, Novak RM, Patel MV, Sriprasert I, Thurman AR, Yegorov S, Mugo NR, Roxby AC, Micks E, Hladik F; Consortium for Assessing Immunity Across the Menstrual Cycle. Hughes SM, et al. Among authors: castle pe. BMC Med. 2022 Oct 5;20(1):353. doi: 10.1186/s12916-022-02532-9. BMC Med. 2022. PMID: 36195867 Free PMC article.
Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol.
Murenzi G, Shumbusho F, Hansen N, Munyaneza A, Gage JC, Muhoza B, Kanyabwisha F, Pierz A, Tuyisenge P, Anastos K, Castle PE. Murenzi G, et al. Among authors: castle pe. BMJ Open. 2022 Aug 25;12(8):e061650. doi: 10.1136/bmjopen-2022-061650. BMJ Open. 2022. PMID: 36008069 Free PMC article.
INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have been shown to be highly effective in protecting women against cervical infections, high-grade abnormalities and cancer caused by the targeted HPV types. ...We will also compare the HPV …
INTRODUCTION: Prophylactic human papillomavirus (HPV) vaccines have been shown to be highly effective in protecting women against cer …
HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.
Aasbø G, Tropè A, Nygård M, Christiansen IK, Baasland I, Iversen GA, Munk AC, Christiansen MH, Presthus GK, Undem K, Bjørge T, Castle PE, Hansen BT. Aasbø G, et al. Among authors: castle pe. Br J Cancer. 2022 Nov;127(10):1816-1826. doi: 10.1038/s41416-022-01954-9. Epub 2022 Aug 23. Br J Cancer. 2022. PMID: 35995936 Free PMC article. Clinical Trial.
BACKGROUND: Cervical cancer screening participation is suboptimal in most settings. We assessed whether human papillomavirus (HPV) self-sampling may increase screening participation among long-term non-attenders in Norway. ...A random sample of 6000 women aged 35-69 …
BACKGROUND: Cervical cancer screening participation is suboptimal in most settings. We assessed whether human papillomavirus (HPV …
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors.
Jackson SS, Marks MA, Katki HA, Cook MB, Hyun N, Freedman ND, Kahle LL, Castle PE, Graubard BI, Chaturvedi AK. Jackson SS, et al. Among authors: castle pe. Cancer. 2022 Oct 1;128(19):3531-3540. doi: 10.1002/cncr.34390. Epub 2022 Aug 8. Cancer. 2022. PMID: 35934938 Free article.
Cancer-specific Cox regression models were used to estimate male-to-female hazard ratios (HRs). ...At most other anatomic sites, the risks were higher in men than in women (adjusted HR range, 1.3-10.8), with the strongest increases for bladder cancer (HR, 3.33; 95% …
Cancer-specific Cox regression models were used to estimate male-to-female hazard ratios (HRs). ...At most other anatomic sites, the …
A comparison of high-grade cervical abnormality risks in women living with and without human immunodeficiency virus undergoing routine cervical-cancer screening.
Castle PE, Befano B, Schiffman M, Wentzensen N, Lorey T, Poitras N, Hyer M, Cheung LC. Castle PE, et al. Prev Med. 2022 Sep;162:107157. doi: 10.1016/j.ypmed.2022.107157. Epub 2022 Jul 8. Prev Med. 2022. PMID: 35810936 Free PMC article.
As the US moves increasingly towards using human papillomavirus (HPV) testing with or without concurrent cytology for cervical cancer screening, it is unknown what the corresponding risks are following a screening result for women living with HIV (WLWH), which will …
As the US moves increasingly towards using human papillomavirus (HPV) testing with or without concurrent cytology for cervical can …
Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway.
Nygård M, Engesæter B, Castle PE, Berland JM, Eide ML, Iversen OE, Jonassen CM, Christiansen IK, Vintermyr OK, Tropé A. Nygård M, et al. Among authors: castle pe. Cancer Epidemiol Biomarkers Prev. 2022 Sep 2;31(9):1812-1822. doi: 10.1158/1055-9965.EPI-22-0340. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35793700 Free PMC article. Clinical Trial.
BACKGROUND: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). ...HPV-based screening prot …
BACKGROUND: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus …
Different human papillomavirus types share early natural history transitions in immunocompetent women.
Adebamowo SN, Befano B, Cheung LC, Rodriguez AC, Demarco M, Rydzak G, Chen X, Porras C, Herrero R, Kim JJ, Castle PE, Wentzensen N, Kreimer AR, Schiffman M, Campos NG. Adebamowo SN, et al. Among authors: castle pe. Int J Cancer. 2022 Sep 15;151(6):920-929. doi: 10.1002/ijc.34128. Epub 2022 Jun 17. Int J Cancer. 2022. PMID: 35603904 Free PMC article.
Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS-LSIL Triage Study (ALTS) and the Costa Rica HPV Vaccine Trial (CVT), we compared the early natural history of HPV types to inform transition probabi …
Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS-LSIL Triage Study (ALT …
Evaluation of a 2-1-1 Telephone Navigation Program to Increase Cancer Control Behaviors: Results From a Randomized Controlled Trial.
Fernandez ME, Savas LS, Atkinson JS, Ricks KB, Ibekwe LN, Jackson I, Castle PE, Jobe D, Vernon SW. Fernandez ME, et al. Among authors: castle pe. Am J Health Promot. 2022 Sep;36(7):1083-1093. doi: 10.1177/08901171211041276. Epub 2022 May 5. Am J Health Promot. 2022. PMID: 35514063 Free PMC article. Clinical Trial.
PARTICIPANTS: 2-1-1 callers in need of Pap test, mammography, colorectal cancer screening, smoking cessation counseling, and/or HPV vaccination for a daughter (n = 1,554). ...Other outcomes showed the same trend although the difference was not statistically signific …
PARTICIPANTS: 2-1-1 callers in need of Pap test, mammography, colorectal cancer screening, smoking cessation counseling, and/or HP …
Prevalence and factors associated with human Taenia solium taeniosis and cysticercosis in twelve remote villages of Ranomafana rainforest, Madagascar.
Rahantamalala A, Rakotoarison RL, Rakotomalala E, Rakotondrazaka M, Kiernan J, Castle PM, Hakami L, Choi K, Rafalimanantsoa AS, Harimanana A, Wright P, Grandjean Lapierre S, Schoenhals M, Small PM, Marcos LA, Vigan-Womas I. Rahantamalala A, et al. Among authors: castle pm. PLoS Negl Trop Dis. 2022 Apr 11;16(4):e0010265. doi: 10.1371/journal.pntd.0010265. eCollection 2022 Apr. PLoS Negl Trop Dis. 2022. PMID: 35404983 Free PMC article.
Reply to: Comments on "Meta-analysis of agreement/concordance statistics in studies comparing self- vs clinician-collected samples for HPV testing in cervical cancer screening".
Sahasrabuddhe VV, Castle PE, Schiffman M, Wentzensen N, Heckman-Stoddard B, Arbyn M. Sahasrabuddhe VV, et al. Among authors: castle pe. Int J Cancer. 2022 Aug 1;151(3):484-487. doi: 10.1002/ijc.34013. Epub 2022 Apr 18. Int J Cancer. 2022. PMID: 35377490 Free article. No abstract available.
National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA, Sherrah M, Sultana F, Castle PE, Arbyn M, Gertig D, Caruana M, Wrede CD, Saville M, Canfell K. Smith MA, et al. Among authors: castle pe. BMJ. 2022 Mar 30;376:e068582. doi: 10.1136/bmj-2021-068582. BMJ. 2022. PMID: 35354610 Free PMC article.
OBJECTIVE: To review the first two years of the primary human papillomavirus (HPV) cervical screening programme in an HPV vaccinated population. ...HPV16/18 driven referrals were low in HPV vaccinated cohorts....
OBJECTIVE: To review the first two years of the primary human papillomavirus (HPV) cervical screening programme in an HPV vacc …
Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus.
Cohen CM, Wentzensen N, Lahrmann B, Tokugawa D, Poitras N, Bartels L, Krauthoff A, Keil A, Miranda F, Castle PE, Lorey T, Hare B, Darragh TM, Grabe N, Clarke MA. Cohen CM, et al. Among authors: castle pe. Clin Infect Dis. 2022 Oct 29;75(9):1565-1572. doi: 10.1093/cid/ciac211. Clin Infect Dis. 2022. PMID: 35325073 Free PMC article.
BACKGROUND: Human papillomavirus-related biomarkers such as p16/Ki-67 "dual-stain" (DS) cytology have shown promising clinical performance for anal cancer screening. Here, we assessed the performance of automated evaluation of DS cytology (automated DS) to detect anal prec …
BACKGROUND: Human papillomavirus-related biomarkers such as p16/Ki-67 "dual-stain" (DS) cytology have shown promising clinical performance f …
The iBreastExam versus clinical breast examination for breast evaluation in high risk and symptomatic Nigerian women: a prospective study.
Mango VL, Olasehinde O, Omisore AD, Wuraola FO, Famurewa OC, Sevilimedu V, Knapp GC, Steinberg E, Akinmaye PR, Adewoyin BD, Romanoff A, Castle PE, Alatise O, Kingham TP. Mango VL, et al. Among authors: castle pe. Lancet Glob Health. 2022 Apr;10(4):e555-e563. doi: 10.1016/S2214-109X(22)00030-4. Lancet Glob Health. 2022. PMID: 35303464 Free PMC article.
Participants were Nigerian women aged 40 years or older who were symptomatic and presented with breast cancer symptoms or those at high risk with a first-degree relative who had a history of breast cancer. ...Further research into improved specificity with device up …
Participants were Nigerian women aged 40 years or older who were symptomatic and presented with breast cancer symptoms or those at hi …
Multi-task network for automated analysis of high-resolution endomicroscopy images to detect cervical precancer and cancer.
Brenes D, Barberan CJ, Hunt B, Parra SG, Salcedo MP, Possati-Resende JC, Cremer ML, Castle PE, Fregnani JHTG, Maza M, Schmeler KM, Baraniuk R, Richards-Kortum R. Brenes D, et al. Among authors: castle pe. Comput Med Imaging Graph. 2022 Apr;97:102052. doi: 10.1016/j.compmedimag.2022.102052. Epub 2022 Feb 26. Comput Med Imaging Graph. 2022. PMID: 35299096 Free PMC article.
Performance was comparable to expert colposcopy with a test sensitivity and specificity of 0.94 (p = 0.3) and 0.58 (p = 1.0), respectively. Patients with recurrent human papillomavirus (HPV) infections are at a higher risk of developing cervical cancer. Thus, we sou …
Performance was comparable to expert colposcopy with a test sensitivity and specificity of 0.94 (p = 0.3) and 0.58 (p = 1.0), respectively. …
Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results.
Demarco M, Egemen D, Hyun N, Chen X, Moscicki AB, Cheung L, Carter-Pokras O, Hammer A, Gage JC, Clarke MA, Castle PE, Befano B, Chen J, Dallal C, He X, Desai K, Lorey T, Poitras N, Raine-Bennett TR, Perkins RB, Wentzensen N, Schiffman M. Demarco M, et al. Among authors: castle pe. J Low Genit Tract Dis. 2022 Apr 1;26(2):127-134. doi: 10.1097/LGT.0000000000000667. J Low Genit Tract Dis. 2022. PMID: 35249974 Free PMC article.
MATERIALS AND METHODS: We analyzed data from HPV-infected women, ages 30-65 years, in the National Cancer Institute-Kaiser Permanente Northern California Persistence and Progression study. We estimated the influence of HPV risk group, cytology result, and sel …
MATERIALS AND METHODS: We analyzed data from HPV-infected women, ages 30-65 years, in the National Cancer Institute-Kaiser Per …
522 results